Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 11,950.0 | 11,611.0 | 11,703.0 | 12,110.0 | 11,303.0 | 10,190.0 | 7,537.0 | 7,541.0 |
| Revenue growth | 2.9% | -0.8% | -3.4% | 7.1% | 10.9% | 35.2% | -0.1% | 3.5% |
| Cost of goods sold | 4,998.0 | 4,939.0 | 5,011.0 | 5,280.0 | 4,855.0 | 4,793.0 | 4,505.0 | 4,521.0 |
| Gross profit | 6,952.0 | 6,672.0 | 6,692.0 | 6,830.0 | 6,448.0 | 5,397.0 | 3,032.0 | 3,020.0 |
| Gross margin | 58.2% | 57.5% | 57.2% | 56.4% | 57.0% | 53.0% | 40.2% | 40.0% |
| Selling, general and administrative | 3,763.0 | 3,764.0 | 4,302.0 | 3,926.0 | 3,505.0 | 2,484.0 | | |
| Research and development | 1,661.0 | 1,550.0 | 1,465.0 | 1,324.0 | 1,167.0 | 1,105.0 | 1,022.0 | 976.0 |
| General and administrative | | | | | | | 490.0 | 440.0 |
| EBITA | 3,499.0 | 3,192.0 | 2,703.0 | 3,154.0 | 3,423.0 | 2,558.0 | 2,552.0 | 2,830.0 |
| EBITA margin | 29.3% | 27.5% | 23.1% | 26.0% | 30.3% | 25.1% | 33.9% | 37.5% |
| Amortization of intangibles | 245.0 | 234.0 | 236.0 | 226.0 | 214.0 | 207.0 | 197.0 | 222.0 |
| EBIT | 3,254.0 | 2,958.0 | 2,467.0 | 2,928.0 | 3,209.0 | 2,351.0 | 2,355.0 | 2,608.0 |
| EBIT margin | 27.2% | 25.5% | 21.1% | 24.2% | 28.4% | 23.1% | 31.2% | 34.6% |
| Pre-tax income | 3,171.0 | 2,899.0 | 2,712.0 | 3,101.0 | 2,995.0 | 2,120.0 | 2,298.0 | 2,437.0 |
| Income taxes | 478.0 | 479.0 | 470.0 | 508.0 | 839.0 | -22.0 | 318.0 | 415.0 |
| Tax rate | 15.1% | 16.5% | 17.3% | 16.4% | 28.0% | | 13.8% | 17.0% |
| Net income | 2,572.0 | 2,257.0 | 2,009.0 | 2,404.0 | 1,972.0 | 1,968.0 | 1,848.0 | 1,958.0 |
| Net margin | 21.5% | 19.4% | 17.2% | 19.9% | 17.4% | 19.3% | 24.5% | 26.0% |
| |
| Diluted EPS | $7.19 | $6.32 | $5.38 | $6.39 | $5.19 | $4.97 | $4.47 | $4.53 |
| Shares outstanding (diluted) | 358.0 | 357.1 | 373.7 | 376.5 | 380.2 | 396.1 | 413.6 | 432.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|